Comparative Pharmacology
Head-to-head clinical analysis: CLARITIN REDITABS versus EVALOSE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLARITIN REDITABS versus EVALOSE.
CLARITIN REDITABS vs EVALOSE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Loratadine is a selective antagonist of peripheral histamine H1 receptors, reducing allergic response symptoms by inhibiting histamine release from mast cells.
EVALOSE is a selective serotonin reuptake inhibitor (SSRI) that potentiates serotonergic activity by blocking the reuptake of serotonin at the presynaptic neuron, thereby increasing serotonin levels in the synaptic cleft.
10 mg orally once daily.
Adults: 1-2 tablets (5-10 mg) orally once daily, adjusted to maximum 20 mg/day.
None Documented
None Documented
Terminal elimination half-life: 8–28 hours (mean ~14 hours for loratadine; active metabolite desloratadine: 14–26 hours). Context: Allows once-daily dosing; half-life extended in hepatic impairment.
Terminal elimination half-life is 12 hours (range 10-14 h); clinically significant for once-daily dosing in most patients with normal renal function; extend dosing interval in renal impairment
Renal (approximately 40% as metabolites) and fecal (approximately 40% as metabolites). Parent drug and active metabolite (desloratadine) are excreted in urine (27% total) and feces (40% total).
Renal: 70% unchanged; Biliary/Fecal: 20% as metabolites; 10% other
Category C
Category C
Antihistamine
Antihistamine